Skip to main content

Table 13 Cost-effectiveness results for low CVD risk males and moderate to very high CVD risk females without and with diabetes. All dominated strategies have been excluded

From: Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study

CVD risk

      

Strategy

Cost

IC

Eff

IE

ICER

Strategy

Cost

IC

Eff

IE

ICER

  Low risk

     

Moderate risk

     

  No treatment

799

 

0.00

  

No treatment

991

 

0.00

  

  ACEI Diu

1202

403

0.61

0.61

661

ACEI Diu

1330

339

0.82

0.82

413

  ACEI Diu Sta

1424

222

0.74

0.13

1708

ACEI Diu Sta

1525

195

1.02

0.20

975

  High risk

     

Very high risk

     

  No treatment

1112

 

0.00

  

No treatment

1591

 

0.00

  

  ACEI CCB Diu

1941

829

1.22

1.22

680

ACEI CCB Diu ASA

3059

1468

2.30

2.30

638

  ACEI CCB Diu Sta

2152

211

1.43

0.21

1005

ACEI CCB Diu Sta ASA

3277

218

2.56

0.26

838

CVD risk with diabetes

      

Strategy

Cost

IC

Eff

IE

ICER

Strategy

Cost

IC

Eff

IE

ICER

  Low risk

     

Moderate risk

     

  No treatment

1175

 

0.00

  

No treatment

1467

 

0.00

  

  Sulf ACEI CCB

1619

444

0.95

0.95

467

Sulf ACEI CCB

1756

289

1.36

1.36

213

  Big Sulf ACEI CCB

1878

259

1.30

0.35

740

Big Sulf ACEI CCB

1971

215

1.94

0.58

371

  Big Sulf ACEI CCB Sta

2110

232

1.42

0.12

1933

Big Sulf ACEI CCB Sta

2182

211

2.13

0.19

1111

  High risk

     

Very high risk

     

  No treatment

1602

 

0.00

  

No treatment

2060

 

0.00

  

  Big Sulf ACEI CCB

2446

844

2.17

2.17

389

Big Sulf ACEI CCB ASA

3539

1479

3.37

3.37

439

  Big Sulf ACEI CCB Sta

2654

208

2.38

0.21

991

Big Sulf ACEI CCB Sta ASA

3757

218

3.64

0.27

807

  Big Sulf ACEI ARB CCB Sta

3700

1046

2.48

0.10

10460

Big Sulf ACEI ARB CCB Sta ASA

4770

1013

3.77

0.13

7792

  1. IC - Incremental cost; Eff - Effectiveness; IE - Incremental effectiveness; ICER - Incremental cost-effectiveness ratio